Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 111250 million in 2024 and is forecast to a readjusted size of USD 490450 million by 2031 with a CAGR of 23.9% during review period.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:
Market Drivers:
Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.
Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.
Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.
Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.
Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.
Market Challenges:
High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.
Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.
Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.
Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.
Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.
Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.
This report is a detailed and comprehensive analysis for global Glucagon Like Peptide-1 (GLP-1) Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Glucagon Like Peptide-1 (GLP-1) Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Glucagon Like Peptide-1 (GLP-1) Agonists market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Glucagon Like Peptide-1 (GLP-1) Agonists market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Dulaglutide
Exenatide
Liraglutide
Benaglutide
Other
Market segment by Application
Diabetes
Obesity
Major players covered
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
GSK
Hanson
Shanghai Benemae
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales quantity, revenue, and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists from 2020 to 2025.
Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Glucagon Like Peptide-1 (GLP-1) Agonists.
Chapter 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:
Market Drivers:
Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.
Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.
Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.
Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.
Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.
Market Challenges:
High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.
Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.
Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.
Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.
Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.
Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.
This report is a detailed and comprehensive analysis for global Glucagon Like Peptide-1 (GLP-1) Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Glucagon Like Peptide-1 (GLP-1) Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Glucagon Like Peptide-1 (GLP-1) Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Glucagon Like Peptide-1 (GLP-1) Agonists market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Glucagon Like Peptide-1 (GLP-1) Agonists market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Dulaglutide
Exenatide
Liraglutide
Benaglutide
Other
Market segment by Application
Diabetes
Obesity
Major players covered
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
GSK
Hanson
Shanghai Benemae
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales quantity, revenue, and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists from 2020 to 2025.
Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Glucagon Like Peptide-1 (GLP-1) Agonists.
Chapter 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion.
Table of Contents
94 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
